An advisory panel for the Food and Drug Administration is scheduled to meet on November 3 to consider making the OraQuick rapid HIV antibody test available for over-the-counter purchase and home use, The New York Times reports. The test, called the OraQuick Advance Rapid HIV 1/2 Antibody Test, can produce results in about 20 minutes from oral samples. The tests are currently available only to doctors, HIV clinics, and AIDS service organizations that conduct street-level testing programs, but the FDA panel is expected to recommend that they be available directly to consumers.
The test is simple to use, says developer OraSure Technologies. Users swab their gums and place the swab in a holder. After 20 minutes, one line will appear on the holder if the test is negative for HIV infection, and two lines if the test result is positive. Its ease of use makes it ideal for home use by adults who may be too nervous to seek testing from their doctors or an HIV clinic or are afraid of the stigma associated with possibly receiving positive test results at a public testing facility, proponents say. At-home testing also could help identify the estimated one third of Americans who are HIV-positive but unaware they’re infected.
But many AIDS advocates and health officials say at-home testing could be dangerous because there is no counseling component involved, and those who test positive may panic and possibly attempt suicide with no one there to talk with them about their results and their options for treatment and support.
OraSure president Douglas Michels says the company would include any FDA-recommended advice about counseling on the product’s label—including referrals to a 24-hour counseling center, a hotline number, Internet support, and printed material—if it were approved for over-the-counter sales. (Advocate.com)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.